OTTAWA—The federal government is overhauling the way it regulates the cost of patented medicines, including ending comparisons to the United States—changes that Canada’s health minister is billing as the biggest step towards lower drug prices in a generation.
Health Canada’s long-awaited amendments to patented medicine regulations, unveiled Friday, include allowing the arm’s-length Patented Medicine Prices Review Board to consider whether the price of a drug reflects the value it has for patients.
